DSpace/Dipòsit Manakin

Current developments in gastric cancer: from molecular profiling to treatment strategy

Current developments in gastric cancer: from molecular profiling to treatment strategy
 
Alsina, Maria ; Arrazubi, Virginia ; Diez, Marc ; Tabernero, Josep
2023

Text complet d'aquest document

Icon
Nom: artconlli_a2023_tabernero_josep_current_developments.pdf
Mida: 1.748Mb
Format: PDF
Descripció: Accés restringit. Cliqueu la icona per sol·licitar una còpia.
Enllaç permanent: http://hdl.handle.net/10854/7829
 
Versió de l'editor: https://doi.org/10.1038/s41575-022-00703-w
 

Resum:

Gastric cancer and gastro-oesophageal junction cancer represent a global health-care challenge. Despite the efficacy of improved chemotherapy and surgical options, these patients still have a poor prognosis. In advanced disease, only trastuzumab and some immune checkpoint inhibitors, such as nivolumab and pembrolizumab ...»»»»
Gastric cancer and gastro-oesophageal junction cancer represent a global health-care challenge. Despite the efficacy of improved chemotherapy and surgical options, these patients still have a poor prognosis. In advanced disease, only trastuzumab and some immune checkpoint inhibitors, such as nivolumab and pembrolizumab in addition to chemotherapy, have demonstrated consistent and reliable efficacy in patients with HER2-positive and PDL1-positive tumours, respectively. In this Review, we discuss the intrinsic characteristics of gastric and gastro-oesophageal cancer from the molecular and clinical perspectives and provide a comprehensive review of previously reported and ongoing phase II and III clinical trials with targeted agents and immunotherapy in advanced and localized settings. Finally, we suggest alternative strategies to help overcome current challenges in precision medicine and to improve outcomes for these patients.^^^^

Tipus:

Article

Indexació:

 
Indexat a WOS/JCR
 
Indexat a SCOPUS
 

Drets:

Tots els drets reservats

Citació Bibliogràfica:

Alsina, M., Arrazubi, V., Diez, M. et al. Current developments in gastric cancer: from molecular profiling to treatment strategy. Nat Rev Gastroenterol Hepatol 20, 155–170 (2023). https://doi.org/10.1038/s41575-022-00703-w